SciBase’s Nevisense Gains U.S. Patent Approval

SciBase’s Nevisense malignant melonoma-detection method has received U.S. patent approval, the Swedish devicemaker announced Monday.

Nevisense relies on electrical impedance spectroscopy technology to classify cellular structures, detecting malignancies in the process.

Specifically, the device’s electrodes equipped with micro-needles measure skin cells’ electrical properties for abnormalities.

This technology can be used to potentially detect other types of cancer, says CEO Simon Grant.

The device has won CE Mark and TGA approval, with FDA clearance pending. SciBase holds 49 registered patents valid until 2023, with another 12 patent applications in review.

Skin cancer is the most diagnosed cancer worldwide. Malignant melanoma is its most deadly form, accounting for 75 percent of skin cancer-related deaths. — Jason Scott